Industry Revenue Breakdown:

• Dietary Supplements: approx. 70%
• Health Products: approx. 20%
• Other: approx. 10%

TOP 3 Markets:

• China: approx. 60%
• USA: approx. 20%
• Europe: approx. 10%

Byhealth Co., Ltd generates the majority of its revenue from the sale of dietary supplements, accounting for approximately 70% of total revenue. This reflects the company's strong market position in this segment. Health products contribute about 20% to the revenue, while other products make up the remaining 10%.

Geographically, China is the primary market for Byhealth, representing around 60% of total revenue. The USA and Europe follow with 20% and 10% respectively, highlighting the company's international presence and strategic expansion in these markets.

Production Sites: Guangzhou, China; Zhuhai, China

Byhealth Co., Ltd is a leading company in the field of dietary supplements in China. The main production facilities are located in Guangzhou and Zhuhai. These sites are strategically chosen to efficiently serve both domestic demand and support exports. The modern production plants are equipped with advanced technology to ensure the quality and efficiency of manufacturing.

Revenue Growth: 10.5% (2025) Research & Development Investments: 8% of revenue (2025)

Byhealth Co., Ltd pursues a strategy that heavily focuses on innovation and expansion into new markets. The company continuously invests in research and development to develop new products that meet changing consumer needs. These investments account for approximately 8% of revenue and are a key component of the growth strategy.

In addition, Byhealth is focusing on expanding into international markets, particularly in Asia and Europe, to strengthen its global presence. Partnerships and strategic alliances with local companies are intended to help overcome market entry barriers and increase brand awareness.

Another focus is on digitization and expanding the e-commerce business to increase reach and engage directly with end consumers. This is supported by investments in digital platforms and data-driven marketing strategies.

Imported raw materials: Vitamins, minerals, herbal extracts

Main importing countries: USA, Germany, China, India

Byhealth Co., Ltd imports a variety of raw materials necessary for the production of their dietary supplements. These include vitamins and minerals, which are often sourced from the USA and Germany, as these countries are known for their high-quality pharmaceutical products.

Herbal extracts and other plant-based ingredients are frequently imported from China and India, as these countries have a long tradition and expertise in the production of herbal products. The selection of supplier countries is based on the availability of raw materials, product quality, and costs.

Market share in the dietary supplements industry: 12% (2025, estimate) R&D investments: 8% of revenue (2025) Brand awareness in China: High

Byhealth Co., Ltd has a significant competitive advantage in the dietary supplements industry, especially in China. The company benefits from strong brand awareness and a wide product portfolio targeting the growing demand for health products.

A key factor for the competitive advantage is the continuous investment in research and development, accounting for about 8% of revenue. This enables Byhealth to develop innovative products and differentiate itself from competitors.

Furthermore, through strategic partnerships and an effective distribution strategy, Byhealth has strengthened its market position. The market share of about 12% indicates that the company plays a leading role in the industry, further supporting its competitiveness.

Institutional Investor Share: Estimated around 45% (2026)
Insider Buys/Sells: No significant transactions in the last year (2025)

The institutional investor share in Byhealth Co., Ltd is estimated to be around 45%. This demonstrates the confidence of institutional investors in the company and its market position.

In 2025, there were no significant insider transactions, which could indicate a stable assessment of the company's value by management. A lack of insider buys or sells may also suggest that management does not anticipate short-term changes in the company's value.

Market share of Byhealth Co., Ltd: 12% (2026, estimated)

Top competitors and their market shares:

1. Amway (China) Co., Ltd: 18%
2. Herbalife Nutrition Ltd: 15%
3. Usana Health Sciences, Inc.: 10%
4. GNC Holdings, Inc.: 8%
5. Blackmores Limited: 7%

Byhealth Co., Ltd holds a significant market share of 12% in the area of dietary supplements in China. This positions the company as one of the leading players in this market segment. The biggest competitor, Amway, holds a market share of 18%, followed by Herbalife with 15%.

The moat of Byhealth Co., Ltd mainly consists of strong brand recognition in China, a wide product portfolio, and an established distribution structure. These factors provide the company with a certain competitive advantage over smaller players.

However, some competitors, such as Amway and Herbalife, may have a stronger moat due to their global presence, extensive research and development capabilities, and established international networks. These companies can benefit from economies of scale and broader market penetration, which could strengthen their competitive advantage.

Overall, Byhealth Co., Ltd has a respectable market share and some competitive advantages, but global competitors may be superior in certain aspects.

Revenue Growth: 10.5% (2025)
Profit Growth: 8.2% (2025)
Market Share in China: 20% (2025)

Byhealth Co., Ltd recorded a solid revenue growth of 10.5% in 2025, attributed to strong demand for its health and nutritional supplements. The company has further strengthened its market position in China, holding a 20% market share, making it one of the leading providers in this sector.

The profit growth of 8.2% in 2025 indicates that Byhealth is able to effectively manage its costs while increasing profitability. Investments in research and development, as well as expanding its product range, could further support future growth.

Given these positive financial developments and strong market position, Byhealth Co., Ltd could be an attractive investment opportunity for investors interested in long-term growth in the healthcare sector. However, potential investors should also consider the general economic conditions and regulatory risks in the industry.

Dividend Yield: 2.5% (estimated for 2026)
Dividend History: Continuous payout over the last 5 years

Byhealth Co., Ltd has pursued a consistent dividend policy in recent years. The dividend yield is estimated to be around 2.5% for 2026, based on the latest available financial reports and the company's dividend history.

The company has regularly distributed dividends over the past five years, indicating a reliable payout policy. This stability is supported by a solid financial foundation and steady revenue growth, further reinforcing the company's ability to pay dividends.